EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.

Trial Details

NCT ID
NCT07262619
Phase
PHASE1 / PHASE2
Sponsor
Eikon Therapeutics
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • EIK1005
  • pembrolizumab (KEYTRUDA® )
Locations (sample)
  • Morristown, New Jersey, United States|40.79677,-74.48154
  • New York, New York, United States|40.71427,-74.00597
  • Houston, Texas, United States|29.76328,-95.36327
  • Saint Leonards, New South Wales, Australia
  • Waratah, New South Wales, Australia|-32.90667,151.72647

Key Eligibility Criteria

  • is ≥ 18 years of age at the time of signing the informed consent.
  • has a life expectancy of at least 3 months.
  • has histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor. Part 1A: recommend that participants have arc…
  • In Part 1A, has received and then progressed after or is intolerant to at least 1 standard treatment regimen in the advanced setting. The participa…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →